Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Fraser

Showing results (561-570 of 598) with videos related to

Pageof 60
Sort By:
JACC. Cardiovascular Interventions|June 30, 2025
30-Day and 1-Year Outcomes From the Optimize PRO TAVR Evolut FX Addendum StudyHemal Gada, Ramzi F Khalil, Stanley J Chetcuti, et al.
NPJ Breast Cancer|January 10, 2023
Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancerGloria V Echeverria, Shirong Cai, Yizheng Tu, et al.
Cell Reports. Medicine|June 5, 2024
Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness"Bora Lim, Sahil Seth, Clinton Yam, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|November 13, 2019
Initial experience of a self-expanding transcatheter aortic valve with an outer pericardial wrap: The United Kingdom and Ireland Implanters' registryCameron Dowling, Sami Firoozi, Vasileios Panoulas, et al.
The Science of the Total Environment|February 3, 2024
Current extent and future opportunities for living shorelines in AustraliaRebecca L Morris, Erin Campbell-Hooper, Elissa Waters, et al.
Cell Reports. Medicine|December 12, 2023
Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 TrialRosa I Gallagher, Julia Wulfkuhle, Denise M Wolf, et al.
JCO Precision Oncology|June 17, 2025
Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 TrialDenise M Wolf, Christina Yau, Michael Campbell, et al.
Oncogene|December 16, 2020
Hormonal modulation of ESR1 mutant metastasisGuowei Gu, Lin Tian, Sarah K Herzog, et al.
Medrxiv : the Preprint Server for Health Sciences|May 25, 2026
Development and Validation of a Multimodal Clinical, Pathologic, and Genomic Model for Breast Cancer RecurrenceNgoc-Kim Nguyen, Anran Li, Sara Kochanny, et al.
Annals of Surgical Oncology|August 23, 2025
Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical TrialJulie Van Hassel, Katrina Dimitroff, Christina Yau, et al.
Pageof 60

Showing results (561-570 of 598) with videos related to

Sort By:
Pageof 60
JACC. Cardiovascular Interventions|June 30, 2025
30-Day and 1-Year Outcomes From the Optimize PRO TAVR Evolut FX Addendum StudyHemal Gada, Ramzi F Khalil, Stanley J Chetcuti, et al.
NPJ Breast Cancer|January 10, 2023
Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancerGloria V Echeverria, Shirong Cai, Yizheng Tu, et al.
Cell Reports. Medicine|June 5, 2024
Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness"Bora Lim, Sahil Seth, Clinton Yam, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|November 13, 2019
Initial experience of a self-expanding transcatheter aortic valve with an outer pericardial wrap: The United Kingdom and Ireland Implanters' registryCameron Dowling, Sami Firoozi, Vasileios Panoulas, et al.
The Science of the Total Environment|February 3, 2024
Current extent and future opportunities for living shorelines in AustraliaRebecca L Morris, Erin Campbell-Hooper, Elissa Waters, et al.
Cell Reports. Medicine|December 12, 2023
Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 TrialRosa I Gallagher, Julia Wulfkuhle, Denise M Wolf, et al.
JCO Precision Oncology|June 17, 2025
Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 TrialDenise M Wolf, Christina Yau, Michael Campbell, et al.
Oncogene|December 16, 2020
Hormonal modulation of ESR1 mutant metastasisGuowei Gu, Lin Tian, Sarah K Herzog, et al.
Medrxiv : the Preprint Server for Health Sciences|May 25, 2026
Development and Validation of a Multimodal Clinical, Pathologic, and Genomic Model for Breast Cancer RecurrenceNgoc-Kim Nguyen, Anran Li, Sara Kochanny, et al.
Annals of Surgical Oncology|August 23, 2025
Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical TrialJulie Van Hassel, Katrina Dimitroff, Christina Yau, et al.
Pageof 60